Drug Rehab Facility Evaluation Checklist for Patients and Families

Selecting a drug rehabilitation facility involves assessing dozens of operational, clinical, regulatory, and financial variables — many of which are not visible in facility marketing materials. This page provides a structured evaluation framework drawn from federal agency standards, accreditation criteria, and publicly codified treatment guidelines. The checklist is organized to help patients and families apply consistent criteria across facilities and identify gaps that may affect treatment quality, safety, or continuity of care.

Definition and Scope

A drug rehab facility evaluation checklist is a structured reference tool used to compare treatment programs against a defined set of regulatory, clinical, and operational benchmarks. The scope of any rigorous evaluation spans licensing and accreditation status, clinical staffing ratios, treatment modality mix, levels of care aligned with ASAM criteria, insurance and financial transparency, and aftercare planning infrastructure.

The Substance Abuse and Mental Health Services Administration (SAMHSA) maintains the National Survey of Substance Abuse Treatment Services (N-SSATS), which collects facility-level data including service types, special populations served, and payment options. SAMHSA's Behavioral Health Treatment Locator (findtreatment.gov) draws from this dataset and provides a baseline for initial facility identification, but does not assess quality.

Evaluation checklists divide roughly into two categories:

• Regulatory compliance checklists — verify that a facility holds required state licensure and federal certifications (e.g., SAMHSA OTP certification for methadone programs under 42 CFR Part 8)
• Clinical quality checklists — assess whether a facility applies evidence-based practices aligned with published standards such as SAMHSA's Treatment Improvement Protocols (TIPs) and the American Society of Addiction Medicine (ASAM) Patient Placement Criteria

These two categories are complementary, not interchangeable. A facility may hold all required licenses while delivering care that diverges substantially from evidence-based protocols. Understanding this distinction is foundational to meaningful evaluation.

How It Works

A structured facility evaluation proceeds in discrete phases, each building on the prior.

1. Licensing and accreditation verification — Confirm active state licensure through the relevant state behavioral health authority. Confirm whether the facility holds accreditation from The Joint Commission or CARF International. CARF accreditation requires a facility to demonstrate conformance with over 1,500 standards across domains including person-centered planning, safety, and outcomes measurement.

2. Level of care assessment — Determine whether the facility offers the level of care appropriate to the clinical presentation, using ASAM's six-level framework (0.5 through 4.0). Facilities should be able to articulate their placement criteria explicitly. Mismatched placement — placing a patient requiring ASAM Level 3.7 (medically monitored intensive inpatient) into Level 1 outpatient — carries documented risk of treatment failure.

3. Staffing and credentials review — Request the facility's staffing model. Evaluate whether licensed addiction counselors, licensed clinical social workers, and physicians credentialed in addiction medicine (addiction medicine specialists) are present. The ASAM does not set legally binding staffing ratios, but its 2023 Clinical Practice Guidelines provide reference benchmarks.

4. Treatment modality documentation — Confirm that behavioral therapies offered are evidence-based and listed in SAMHSA's National Registry of Evidence-based Programs and Practices (NREPP). Confirm availability of medication-assisted treatment where clinically indicated, including buprenorphine, methadone, and naltrexone.

5. Co-occurring disorder capacity — Verify whether the facility provides integrated dual-diagnosis treatment or only refers co-occurring mental health conditions to external providers. SAMHSA classifies programs by capability: dual diagnosis capable (DDC) vs. dual diagnosis enhanced (DDE).

6. Financial and insurance transparency — Request a written breakdown of costs, accepted insurance, and any out-of-pocket obligations before admission. Verify coverage applicability under the Affordable Care Act's essential health benefits mandate, which requires substance use disorder treatment coverage in qualified health plans.

7. Aftercare and continuing care planning — Evaluate whether the facility documents a formal continuing care plan at admission, not only at discharge. Research published in the Journal of Substance Abuse Treatment identifies continuing care planning as one of the strongest predictors of sustained recovery outcomes.

Common Scenarios

Scenario 1: Evaluating an inpatient facility for opioid dependence
A family member with opioid use disorder requires residential care. Evaluation priorities include confirmation of SAMHSA-certified OTP status if methadone is a treatment option, availability of buprenorphine induction under 21 U.S.C. § 823(g) qualified providers, and documented protocols for medical detox services. Facilities should provide written patient rights documentation at intake, as required under 42 CFR Part 2 confidentiality regulations.

Scenario 2: Evaluating an outpatient program for adolescents
Adolescent drug rehab programs carry additional regulatory and developmental considerations. SAMHSA's TIP 31 (Screening and Assessing Adolescents for Substance Use Disorders) provides age-specific evaluation criteria. Family involvement protocols and school-reintegration planning should be present as documented program components.

Scenario 3: Comparing inpatient vs. intensive outpatient for stimulant use disorder
Stimulant addiction treatment has no FDA-approved pharmacotherapy as of the most recent SAMHSA treatment guidelines; evaluation must prioritize behavioral therapy modality quality. Intensive outpatient programs offering a minimum of 9 hours of structured programming per week meet ASAM Level 2.1 criteria and may be appropriate for stable presentations without significant co-occurring psychiatric conditions.

Decision Boundaries

Certain findings during evaluation represent disqualifying factors rather than areas for further inquiry. Facilities that cannot produce documentation of active state licensure, that lack any form of third-party accreditation, or that cannot identify a licensed clinical supervisor of record fall outside the minimum regulatory threshold established by state behavioral health agencies.

HIPAA (45 CFR Parts 160 and 164) and 42 CFR Part 2 govern confidentiality of substance use disorder records, and a facility's inability to articulate these protections is a documented compliance gap. Facilities should provide written informed consent documentation that references these regulations explicitly.

Financial coercion — including requiring full cash payment before assessment, or conditioning admission on waiving insurance verification — is inconsistent with SAMHSA-recommended ethical intake standards and warrants documented escalation to the relevant state licensing authority.

References

• SAMHSA — National Survey of Substance Abuse Treatment Services (N-SSATS)
• SAMHSA — Treatment Improvement Protocols (TIPs)
• SAMHSA — Find Treatment (findtreatment.gov)
• SAMHSA — OTP Regulations, 42 CFR Part 8
• American Society of Addiction Medicine (ASAM) — Patient Placement Criteria
• CARF International — Behavioral Health Accreditation Standards
• The Joint Commission — Behavioral Health Care Accreditation
• HHS — HIPAA Privacy Rule, 45 CFR Parts 160 and 164
• eCFR — 42 CFR Part 2: Confidentiality of Substance Use Disorder Patient Records
• CMS — Affordable Care Act Essential Health Benefits